Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

Annals of Oncology ◽

10.1093/annonc/mdz247.168 ◽

2019 ◽

Vol 30 ◽

pp. v324

Author(s):

V. Randrian ◽

A. Adenis ◽

J. Desrame ◽

E. Barbier ◽

F. Di Fiore ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

Download Full-text

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study

Digestive and Liver Disease ◽

10.1016/j.dld.2019.11.014 ◽

2020 ◽

Vol 52 (3) ◽

pp. 347-350

Author(s):

Violaine Randrian ◽

Antoine Adenis ◽

Jérôme Desrame ◽

Emilie Barbier ◽

Frédéric Di Fiore ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

A randomized phase II study of leucovorin, 5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma

Annals of Oncology ◽

10.1093/annonc/mdw371.35 ◽

2016 ◽

Vol 27 ◽

pp. vi218

Author(s):

S.H. Lim ◽

Y.-L. Choi ◽

S.-H. Jung ◽

M.-J.A. Ahn ◽

K. Park ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Node Positive ◽

Randomized Phase Ii ◽

Download Full-text

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma

Advances in Therapy ◽

10.1007/s12325-020-01394-y ◽

2020 ◽

Vol 37 (7) ◽

pp. 3392-3403

Author(s):

Pranav Abraham ◽

Joe Gricar ◽

Ying Zhang ◽

Veena Shankaran

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Treatment Patterns ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

126P A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.147 ◽

2020 ◽

Vol 31 ◽

pp. S1292

Author(s):

J. Chang ◽

H. Wang ◽

Z. Hu ◽

J. Wang ◽

X. Wu ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Download Full-text

Randomized phase II study of recombinant human endostatin combined with definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.4035 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 4035-4035 ◽

Author(s):

Jiahua Lv ◽

Tao Li ◽

Xiaorong Deng ◽

Fang Li ◽

Yanqiong Song ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Locally Advanced ◽

Definitive Chemoradiotherapy ◽

Recombinant Human Endostatin ◽

Randomized Phase Ii

Download Full-text

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Cancer Management and Research ◽

10.2147/cmar.s335515 ◽

2021 ◽

Vol Volume 13 ◽

pp. 8219-8230

Author(s):

Ying-Tao Lin ◽

Ying Chen ◽

Tian-Xiu Liu ◽

Fang Kuang ◽

Ping Huang

Keyword(s):

Squamous Cell Carcinoma ◽

Cost Effectiveness ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

1387P Randomized phase II study comparing docetaxel vs paclitaxel in patients with esophageal squamous cell carcinoma who are refractory to fluoropyrimidine and platinum-based chemotherapy: OGSG1201

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1496 ◽

2021 ◽

Vol 32 ◽

pp. S1051-S1052

Author(s):

H. Hara ◽

S. Yamamoto ◽

T. Kii ◽

R. Kawabata ◽

J. Kawada ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Platinum Based Chemotherapy

Download Full-text

155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study

Annals of Oncology ◽

10.1016/j.annonc.2021.10.174 ◽

2021 ◽

Vol 32 ◽

pp. S1448

Author(s):

M. Lu ◽

X. Yu ◽

Z. Chen ◽

Y. Zhang ◽

Z. Li ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Neuroendocrine Carcinoma ◽

Squamous Cell ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

Download Full-text

Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)

Annals of Oncology ◽

10.1093/annonc/mdw439 ◽

2017 ◽

Vol 28 (1) ◽

pp. 116-120 ◽

Author(s):

M. Yamasaki ◽

T. Yasuda ◽

M. Yano ◽

M. Hirao ◽

K. Kobayashi ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Preoperative Chemotherapy ◽

Squamous Cell ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Resectable Esophageal

Download Full-text

Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2854-0 ◽

2015 ◽

Vol 76 (4) ◽

pp. 829-834 ◽

Author(s):

Jing Tian ◽

Ming Shang ◽

Sheng-Bin Shi ◽

Yong Han ◽

Jun Xu

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text